LCG
CDLX icon

Lisanti Capital Growth’s Cardlytics CDLX Stock Holding History

Lisanti Capital Growth’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,643
Closed -$3.35M – 140
2021
Q2 		$3.35M Sell
2,643
-3,300
-56% -$3.72M 0.42% 90
2021
Q1 		$6.52M Sell
5,943
-566
-9% -$747K 0.84% 52
2020
Q4 		$9.29M Buy
6,509
+3,610
+125% +$3.85M 1.29% 27
2020
Q3 		$2.04M Sell
2,899
-3,655
-56% -$2.66M 0.38% 83
2020
Q2 		$4.59M Buy
6,554
+4,492
+218% +$2.59M 0.93% 47
2020
Q1 		$721K Sell
2,062
-1,351
-40% -$957K 0.24% 97
2019
Q4 		$2.15M Buy
+3,413
New +$1.67M 0.57% 71

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Lisanti Capital Growth's CDLX Position: Q3 2021 in Review

Lisanti Capital Growth sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 2,643 shares — an estimated $3.35M sold.

Lisanti Capital Growth first reported a position in CDLX in Q4 2019 and held it in 7 quarters. The position peaked at $9.29M in Q4 2020. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

  • Lisanti Capital Growth reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
  • Lisanti Capital Growth sold 2,643 Cardlytics shares in Q3 2021, an estimated $3.35M.
  • Lisanti Capital Growth first reported a position in Cardlytics in Q4 2019 and held it in 7 quarters.
  • Lisanti Capital Growth's Cardlytics position peaked at $9.29M in Q4 2020.
  • 164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on Lisanti Capital Growth's 13F filing for Q3 2021, filed 3 Nov 2021.